JSAG Schouten, EC La Heij, CAB Webers, IJ … - Graefe's Archive for …, 2009 - Springer Abstract Aim To provide evidence for the effect of bevacizumab on visual acuity (VA) and central
retinal thickness (CRT) in exudative age-related macular degeneration Methods A systematic
review of all articles of bevacizumab for exudative AMD was conducted. Articles ... Cited by 17 - Related articles - All 2 versions
- ►prsjournal.com TA Ciulla, PJ Rosenfeld - Current Opinion in Ophthalmology, 2009 - journals.lww.com Recent findings: Two anti-VEGF agents, pegaptanib sodium and ranibizumab, are currently approved
by the United States Food and Drug Administration for the treatment of neovascular AMD. In
addition, off-label use of a third anti-VEGF agent, bevacizumab, as a treatment option for ... Cited by 7 - Related articles - All 5 versions
L Wu, J Fernando Arevalo, M Maia, MH Berrocal, J … - Japanese Journal of …, 2009 - Springer Choroidal neovascularization (CNV) is responsible for 80% to 90% of cases of severe vision
loss due to age-related macular degeneration (AMD). 1–3 Vascular endothelial growth factor
(VEGF) appears to play a major role in the pathogenesis of CNV secondary to AMD. 4–7 ... Related articles - All 2 versions
KE Schmid-Kubista, I Krebs, B Gruenberger, F … - British Medical …, 2009 - bjo.bmj.com Methods: Subjects with fibrovascular pigment epithelial detachment, subfoveal choroidal neovascularisation
extending under the geometric centre of the foveal avascular zone and/or macular thickness
of at least 300 µm in both eyes were included. Sixteen eyes were included and ... Related articles - All 7 versions
ML Subramanian, S Ness, G Abedi, E Ahmed, M … - American Journal of …, 2009 - Elsevier This is a single-center, randomized clinical trial at the Boston Veterans Affairs Healthcare
System. Patients who met inclusion criteria were randomized 2:1 to bevacizumab or
ranibizumab. Each patient contributed 1 eye to the study. All subjects and investigators ( ... Related articles - All 2 versions